SCHEMBL5401147

SCHEMBL5401147

CN(C)CCN(Cc1ccccc1)C(=O)c1ccccc1-c1ccccc1C(=O)N(CCC(=O)O)CCc1cccs1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.46
MEN1 O00255 4/20 0.46
TDP1 Q9NUW8 2/20 0.46
TSHR P16473 4/20 0.43
TRPM8 Q7Z2W7 1/20 0.43
LIMK2 P53671 1/20 0.41
POLB P06746 2/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
USP2 O75604 1/20 0.41
ADAM17 P78536 2/20 0.40
ALDH1A1 P00352 5/20 0.40
MAPK1 P28482 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HSP90AA1 P07900 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5405958 0.92 TSHR (0.49) KMT2AMEN1TDP1TSHRTRPM8
SCHEMBL5399274 0.90 KMT2A (0.52) KMT2AMEN1TDP1TSHRTRPM8
SCHEMBL5397119 0.90 ALDH1A1 (0.47) KMT2AMEN1TDP1TSHRTRPM8
SCHEMBL5400554 0.89 LTB4R2 (0.48) KMT2AMEN1TDP1TSHRTRPM8
SCHEMBL5409849 0.88 KMT2A (0.49) KMT2AMEN1TSHRLIMK2ALDH1A1
SCHEMBL5397896 0.87 KMT2A (0.52) KMT2AMEN1TSHRLIMK2ALDH1A1
SCHEMBL5394630 0.85 LPAR1 (0.53) KMT2AMEN1TSHRLIMK2MAPK1
SCHEMBL5400936 0.85 MEN1 (0.43) KMT2AMEN1TDP1TSHRTRPM8
SCHEMBL5398588 0.85 KMT2A (0.45) KMT2AMEN1TSHRLIMK2ALDH1A1
SCHEMBL5412182 0.84 KMT2A (0.47) KMT2AMEN1TSHRLIMK2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB KMT2A 2451/4885MEN1 891/4885TDP1 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.